Akeega Approved for BRCA2-Mutated Prostate Cancer

By News Health
9 hours Ago

(MedPage Today) — The FDA approved niraparib and abiraterone acetate (Akeega) in combination with prednisone for treating BRCA2-mutated metastatic castration-sensitive prostate cancer (mCSPC), the agency announced on Friday.
The once-daily, fixed…

Source link : https://www.medpagetoday.com/hematologyoncology/prostatecancer/119017

Author :

Publish date : 2025-12-15 19:12:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Pyloroplasty With Electric Stimulation Treats Gastroparesis

Six Midlife Depressive Symptoms Tied to Dementia

Not Everyone Gets a Mortality Benefit From Reducing Saturated Fats, Study Says

FDA Approves Sexual Desire Drug for Postmenopausal Women

Aspiring Neurosurgeon Died in Brown Campus Shooting

Smartphone-Delivered Digital Therapy Improved Anxiety Symptoms